Microdialysis Outflow Tube Preservative Infusion for Peptide Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Endogenous opioid peptide-based drugs face enzymatic degradation and poor blood-brain barrier penetration, leading to inaccurate and incomplete results in quantification methods due to peptide degradation in microdialysis outflow tubes before preservative agents can be introduced.
Innovation Solution
Infusing preservative agents, such as acetic acid or formic acid, directly into the outflow tube of microdialysis systems to inhibit degradation of glycosylated peptides, combined with nano LC-MSn for detection and quantification, allowing for precise measurement of endogenous opioid peptides at low concentrations.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If microdialysis is used to collect peptides from brain tissue, then brain permeation can be measured, but peptide degradation occurs in the outflow tube before analysis
Solution Approach 1:
The patent applies preliminary action by adding preservative agents to the outflow tube before peptide degradation can occur. The preservative is introduced upstream to prevent enzymatic degradation during transport, ensuring peptides remain intact for accurate quantification without requiring post-collection intervention.
Solution Approach 2:
The patent uses preservative agents as intermediaries between the peptide sample and the analysis system. These agents mediate protection against degradation by inhibiting enzymes in the outflow tube, creating a stable environment that preserves peptide integrity throughout the transport and analysis process.
2Device complexity
If conventional microdialysis without preservatives is used, then the system is simple, but degradation causes inaccurate and incomplete results
Solution Approach 1:
The preservative is introduced into the outflow tube before peptide degradation occurs, preventing loss of analyte during transport. This preliminary protective action ensures accurate quantification without requiring complex post-collection processing or specialized storage conditions.
Solution Approach 2:
Preservative agents serve as intermediaries that protect peptides from enzymatic degradation in the outflow tube. This simple addition of a protective substance maintains peptide stability without significantly complicating the overall microdialysis system architecture.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The solution effectively reduces peptide degradation, enabling accurate quantification of glycosylated peptides at concentrations as low as 10 pM with a detection limit of 1.5 amol, improving the reliability of blood-brain barrier permeation studies.
Implementation Method 1
a microdialysis probe (with a dialysis membrane) is implanted in the brain, and perfusate having passed through the membrane is collected
Implementation Method 2
preservative agents can be infused directly into the outflow tube to help reduce unwanted degradation of the glycosylated peptides
Implementation Method 3
coupled with mass spectrometry for quantification of blood-brain barrier permeation
Data Source
AI summary
Methods and systems for quantifying blood brain barrier (BBB) permeation of glycosylated peptides. The methods and systems feature microdialysis probes and mechanisms for infusing preservative agents into the outflow tubes of the microdialysis probes. The preservative agents help reduce unwanted degradation of the glycosylated peptides or other compounds, which can lead to a more accurate and complete analysis of the outflow tube perfusate.